These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28273190)

  • 1. [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
    Gaál-Weisinger J; Mucsi O; Körösmezey G; Szili B; Eid H; Kiss R; Bödör C; Tárkányi I; Nagy Z; Demeter J
    Magy Onkol; 2017 Mar; 61(1):67-74. PubMed ID: 28273190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia: Second-line drugs of choice.
    Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
    Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
    Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
    Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
    Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
    Perrone S; Massaro F; Alimena G; Breccia M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia: First-line drug of choice.
    Jabbour E
    Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
    Malkan UY; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current opinions and controversies in chronic myeloid leukaemia.
    Kishore B; Marin D
    Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia.
    Radich JP
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S89-94. PubMed ID: 19254886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular biology and treatment of CML].
    Kimura S
    Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
    Matsumura I
    Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
    Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
    Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.